• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Ambrx Biopharma Inc.

    3/8/23 10:49:34 AM ET
    $AMAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AMAM alert in real time by email
    SC 13D 1 p23-1083sc13d.htm AMBRX BIOPHARMA INC.

     

    SECURITIES AND EXCHANGE COMMISSION  
    Washington, D.C.  20549  
    _______________  
       
    SCHEDULE 13D
     
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
    RULE 13d-2(a)
     
     
    Under the Securities Exchange Act of 1934
    (Amendment No. )*
     

    Ambrx Biopharma Inc.

    (Name of Issuer)
     

    Ordinary Shares, without par value

    (Title of Class of Securities)
     

    02290A102**

    (CUSIP Number)

     

    Abhishek Trehan

    Darwin Global Management, Ltd.

    Whiteley Chambers, Don Street

    St. Helier, Y9 JE2 4TR

    +44 2045 264400

     

    with a copy to:

     

    Eleazer Klein, Esq.
    Adriana Schwartz, Esq.

    Schulte Roth & Zabel LLP

    919 Third Avenue

    New York, NY 10022

    (212) 756-2000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     

    March 6, 2023

    (Date of Event Which Requires Filing of This Statement)
     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. [x] 

     

    (Page 1 of 10 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    **There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 02290A102 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on the New York Stock Exchange under the symbol “AMAM.” Each ADS represents 7 Ordinary Shares.

     

    CUSIP No. 02290A102SCHEDULE 13DPage 2 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

    Darwin Global Management, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) o

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Jersey

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    79,132,011 Ordinary Shares (represented by 11,304,573 ADSs)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    79,132,011 Ordinary Shares (represented by 11,304,573 ADSs)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    79,132,011 Ordinary Shares (represented by 11,304,573 ADSs)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    26.4%

    12

    TYPE OF REPORTING PERSON

    CO, IA

             

     

     

     

     

    CUSIP No. 02290A102SCHEDULE 13DPage 3 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Dr. Abhishek Trehan

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) o

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Britain

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    79,132,011 Ordinary Shares (represented by 11,304,573 ADSs)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    79,132,011 Ordinary Shares (represented by 11,304,573 ADSs)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    79,132,011 Ordinary Shares (represented by 11,304,573 ADSs)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    26.4%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

    CUSIP No. 02290A102SCHEDULE 13DPage 4 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Darwin Global Master Fund, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) o

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    73,370,479 Ordinary Shares (represented by 10,481,497 ADSs)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    73,370,479 Ordinary Shares (represented by 10,481,497 ADSs)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    73,370,479 Ordinary Shares (represented by 10,481,497 ADSs)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    24.5%

    12

    TYPE OF REPORTING PERSON

    CO

             

     

     

     

     

    CUSIP No. 02290A102SCHEDULE 13DPage 5 of 10 Pages

     

    The following constitutes the Schedule 13D filed by the undersigned (the "Schedule 13D").

     

    Item 1. SECURITY AND ISSUER.
       
      This Schedule 13D relates to the Ordinary Shares, without par value (the "Ordinary Shares"), of Ambrx Biopharma Inc. (the "Issuer"). The address of the principal executive offices of the Issuer is 10975 North Torrey Pines Road, La Jolla, CA 92037.

     

    Item 2. IDENTITY AND BACKGROUND.
       
      This statement is filed by the entities and persons listed below:
       
    (a) (i) Darwin Global Management, Ltd., a limited company incorporated under the laws of Jersey (“Darwin Global”). The Ordinary Shares (as defined in Item 2(d) below) represented by ADSs to which this filing relates are held directly by (a) Master Fund (as defined below), to which Darwin Global serves as investment manager and (b) a sub-account (the “Managed Account”) to which Darwin Global serves as sub-advisor;
       
      (ii) Dr. Abhishek Trehan (“Dr. Trehan”), the Chief Investment Officer and the controlling person of Darwin Global, with respect to the Ordinary Shares represented by ADSs held by each of Master Fund and the Managed Account; and
       
      (iii) Darwin Global Master Fund Ltd. (“Master Fund”), a Cayman Islands exempted company, with respect to the Ordinary Shares represented by ADSs held by it.
       
     

    Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons." Each of the Reporting Persons is party to that certain Joint Filing Agreement, as further described in Item 6. Accordingly, the Reporting Persons are hereby filing a joint Schedule 13D.

     

    Set forth in the attached Annex A and incorporated herein by reference is a listing of the directors and controlling persons of the Reporting Persons (collectively, the “Covered Persons”), and sets forth the principal occupation, citizenship and principal place of business of each Covered Person.

       
    (b) The address of the business office of each of the Reporting Persons is Whiteley Chambers, Don Street, St. Helier, Jersey JE2 4TR.

     

    (c) The principal business of Darwin Global is serving as the investment manager of Master Fund. The principal business of Master Fund is serving as the master fund of Darwin Global. Dr. Trehan is the sole shareholder of DGM Holdings, which is the sole shareholder of Darwin Global. Dr. Trehan also serves as a director of Darwin Global.
       
    (d) Neither the Reporting Persons, nor, to the best of their knowledge, any Covered Person, has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
       
    (e) Neither the Reporting Persons, nor, to the best of their knowledge, any Covered Person, has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    CUSIP No. 02290A102SCHEDULE 13DPage 6 of 10 Pages

     

    (f) Darwin Global is a Jersey limited company. Dr. Trehan is a British citizen. Master Fund is a Cayman Islands exempted company.  The citizenship of each Covered Person is set forth on Annex A and incorporated herein by reference.

     

    Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
       
      The securities reported herein were purchased with working capital of the Master Fund in open market purchases, except as indicated otherwise in this Schedule 13D.
       
      The aggregate purchase price of the 79,132,011 Ordinary Shares (represented by 11,304,573 ADSs) reported herein is $47,193,074.92.

     

    Item 4. PURPOSE OF TRANSACTION.
       
      The Reporting Persons purchased the Shares to which this Schedule 13D relates for investment purposes in the ordinary course of business. The Reporting Persons purchased the Shares because they believed that the Shares reported herein, when purchased, represented an attractive investment opportunity.
       
      On March 6, 2023, the Reporting Persons purchased 3,615,000 ADSs through the Issuer’s at-the-market offering (the "ATM Transaction"), which caused their beneficial ownership to exceed 20%.
       
      No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein.

     

      The Reporting Persons intend to review the Reporting Persons’ investment in the Issuer on a continuing basis. The Reporting Persons may seek to sell or otherwise dispose of some or all of the Issuer’s securities from time to time, and/or may seek to acquire additional securities of the Issuer (which may include rights or securities exercisable or convertible into securities of the Issuer) from time to time, in each case, in open market or private transactions, block sales or otherwise.  Any transaction that the Reporting Persons may pursue may be made at any time and from time to time without prior notice and will depend on a variety of factors, including, without limitation, the price and availability of the Issuer’s securities, subsequent developments affecting the Issuer, the Issuer’s business and the Issuer’s prospects, other investment and business opportunities available to the Reporting Persons, general industry and economic conditions, the securities markets in general, tax considerations and other factors deemed relevant by the Reporting Persons.

     

    Item 5. INTEREST IN SECURITIES OF THE ISSUER.
       
    (a) The percentages used in this Schedule 13D are calculated based upon the Reporting Persons' calculation of 299,248,483 Ordinary Shares outstanding, based on the 270,328,483 Ordinary Shares reported outstanding as of June 30 2022 in the Issuer’s Form 6-K filed with the Securities and Exchange Commission on August 29, 2022, and the 25,305,000 Ordinary Shares underlying 3,615,000 ADSs purchased by the Reporting Persons in the ATM Transaction.
       
     

    See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of Common Shares and percentage of the Ordinary Shares beneficially owned by each of the Reporting Persons. The filing of this Schedule 13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer that he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own.

     

    (b) See rows (7) through (10) of the cover pages to this Schedule 13D for the number of Ordinary Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

     

    CUSIP No. 02290A102SCHEDULE 13DPage 7 of 10 Pages
    (c) The transactions in the ADSs effected by the Reporting Persons during the past sixty (60) days are set forth on Schedule 1 attached hereto. Except for the ATM Transaction that took place on March 6, 2023, all transactions in the ADSs during the past sixty (60) days were made on the open market. There were no transactions in the Ordinary Shares.

     

    (d) No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Ordinary Shares.
       
    (e) Not applicable.

     

    Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.
       
      On March 8, 2023, the Reporting Persons entered into a Joint Filing Agreement in which the Reporting Persons agreed to the joint filing on behalf of each of them of statements on Schedule 13D with respect to the securities of the Issuer to the extent required by applicable law. The Joint Filing Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
       
      Other than as described herein, including the information disclosed in Item 4 which is incorporated herein by reference, there are no contracts, arrangements, understandings or relationships among the Reporting Persons, or between the Reporting Persons and any other person, with respect to the securities of the Issuer.

     

    Item 7. MATERIAL TO BE FILED AS EXHIBITS.
       
    Exhibit 99.1: Joint Filing Agreement by and among the Reporting Persons, dated as of March 8, 2023.

     

     

    CUSIP No. 02290A102SCHEDULE 13DPage 8 of 10 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: March 8, 2023

     

     

    DARWIN GLOBAL MANAGEMENT, LTD.  
       
    /s/ John Legge  
    Name: John Legge  
    Title: Director and Chief Financial Officer  
       
       
    /s/ Dr. Abhishek Trehan  
    DR. ABHISHEK TREHAN  
       
       
    DARWIN GLOBAL Master fund, LTD.  
       
    By:  DARWIN GLOBAL MANAGEMENT, LTD, its investment manager  
       
    /s/ John Legge  
    Name: John Legge  
    Title: Director and Chief Financial Officer  

     

     

    CUSIP No. 02290A102SCHEDULE 13DPage 9 of 10 Pages

     

    Schedule 1

     

    Transactions in the AMERICAN DEPOSITORY SHARES of the Issuer During the Last Sixty (60) Days

     

    The following table sets forth all transactions in the ADSs effected in the past sixty days by the Reporting Persons. Except with respect to the ATM Transaction, as noted above, all such transactions were effected in the open market through brokers and the price per share includes commissions. These ADSs were purchased in multiple transactions at prices indicated in the column Price Per ADS ($). The Reporting Persons will undertake to provide to the staff of the SEC, upon request, full information regarding the number of Shares sold at each separate price.

     

    Trade Date ADSs Purchased (Sold) Price Per ADS ($)
    2/27/2023 60,425 $5.48
    2/27/2023 4,702 $5.48
    2/28/2023 37,072 $6.02
    2/28/2023 2,885 $6.02
    3/6/2023 3,355,443 $6.50
    3/6/2023 259,557 $6.50

     

     

     

     

    CUSIP No. 02290A102SCHEDULE 13DPage 10 of 10 Pages

     

    Annex A

    COVERED PERSONS

     

    The following sets forth the name, principal occupation, citizenship or jurisdiction of organization and principal place of business of the directors, general partners, managing members or controlling persons (the "Covered Persons") of the Reporting Persons. Except as set forth in the Schedule 13D, none of the Covered Persons beneficially owns any shares of Ordinary Shares or is party to any contract or agreement as would require disclosure in this Schedule 13D.

     

    Darwin Global Management, Ltd.

     

    Name

    Title or Relationship

    with Reporting Person

    Principal Occupation

    or Employment

    Citizenship or

    Jurisdiction of

    Organization

    Principal Place of

    Business

    DGM Holdings Sole Shareholder Holding Company Cayman Islands (1)
             
    Abhishek Trehan Director Investment Management United Kingdom (2)
             
    John H. Legge Director Accountant United Kingdom (2)
             
    James G. Bryant Director Director United Kingdom (2)

     

    DGM Holdings

     

    Name

    Title or Relationship

    with Reporting Person

    Principal Occupation

    or Employment

    Citizenship or

    Jurisdiction of

    Organization

    Principal Place of

    Business

    Abhishek Trehan Sole Shareholder Investment Management United Kingdom  (2)
             
    Riyaz Nooruddin Director Director United Kingdom (3)

     

    Darwin Global Master Fund, Ltd.

     

    Name

    Title or Relationship

    with Reporting Person

    Principal Occupation

    or Employment

    Citizenship or

    Jurisdiction of

    Organization

    Principal Place of

    Business

             
    Abhishek Trehan Director Investment Management United Kingdom (1)
             
    Alaina Danley Director Director United States (3)
             

    Julian Fletcher

     

    Director Director Canada (4)

     

    (1) 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands

     

    (2) Whiteley Chambers, Don Street, St. Helier, Y9 JE2 4TR, Jersey

     

    (3) P.O. Box 2587, George Town, Grand Cayman KY1-1103, Cayman Islands

     

    (4) Windward 3, Regatta Office Park, West Bay Road, P.O. Box 30872, Grand Cayman KY1-1204, Cayman Islands

    Get the next $AMAM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMAM

    DatePrice TargetRatingAnalyst
    9/25/2023$15.00Mkt Outperform
    JMP Securities
    9/12/2023$26.00Buy
    BTIG Research
    7/31/2023$29.00Outperform
    RBC Capital Mkts
    6/14/2023$26.00Buy
    B. Riley Securities
    6/2/2023$30.00Outperform
    Oppenheimer
    5/19/2023$25.00Overweight
    Cantor Fitzgerald
    4/7/2022$16.00Outperform
    Robert W. Baird
    2/28/2022$6.00Neutral
    Goldman Sachs
    More analyst ratings

    $AMAM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

      – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

      10/29/24 8:00:00 AM ET
      $AMAM
      $KURA
      $RNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ambrx Shareholders Approve Acquisition by Johnson & Johnson

      SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., ("Ambrx" or the "Company") (NASDAQ:AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders. As previously announced, under the terms of the transaction, Ambrx shareholders will receive $28.00 per share in cash in connection with the closing of the transaction. Daniel J. O'Connor, Chief Executive Officer of Ambrx, said, "We want to thank our shareholders for their strong support of this transaction. With a steadfast focus on protein engineering innovation and some of the best ADC talent in t

      3/6/24 1:20:00 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Announces Sale to Johnson & Johnson

      SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ:AMAM), today announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of the outstanding shares of Ambrx for $28.00 per share in cash, representing an approximately 105% premium to Ambrx's closing stock price on January 5, 2024, for a total equity value of approximately $2.0 billion. "We are excited to reach this agreement with Johnson & Johnson for advancing scientific research to treat cancers with high unmet needs," said Daniel J. O'Connor, Chief Executive Officer of Ambrx. "With our deep and unique knowledge of precision engineering of protein ther

      1/8/24 7:35:00 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Cormorant Asset Management, Lp bought $19,625,601 worth of Ordinary Shares (2,152,738 units at $9.12)

      4 - Ambrx Biopharma Inc. (0001836056) (Issuer)

      9/19/23 4:49:06 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    SEC Filings

    See more
    • SEC Form 15-12G filed by Ambrx Biopharma Inc.

      15-12G - Ambrx Biopharma, Inc. (0001990550) (Filer)

      3/18/24 2:45:48 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Biopharma Inc. filed SEC Form 8-K: Leadership Update

      8-K - Ambrx Biopharma, Inc. (0001990550) (Filer)

      3/12/24 4:55:02 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Ambrx Biopharma Inc.

      EFFECT - Ambrx Biopharma, Inc. (0001990550) (Filer)

      3/11/24 12:15:20 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Ambrx Biopharma Inc. (Amendment)

      SC 13G/A - Ambrx Biopharma Cayman, Inc. (0001836056) (Subject)

      2/9/24 5:08:30 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Ambrx Biopharma Inc.

      SC 13G - Ambrx Biopharma Inc. (0001836056) (Subject)

      10/10/23 11:35:22 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Ambrx Biopharma Inc.

      SC 13G - Ambrx Biopharma Inc. (0001836056) (Subject)

      9/25/23 5:24:50 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Leadership Updates

    Live Leadership Updates

    See more
    • Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

      – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

      10/29/24 8:00:00 AM ET
      $AMAM
      $KURA
      $RNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ambrx Appoints Renu Vaish, M.Sc., as Chief Regulatory Officer to Lead Regulatory Affairs

      SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc. ("Ambrx" or the "Company") (NASDAQ:AMAM), today announced the appointment of Renu Vaish, M.Sc., as Chief Regulatory Officer. Ms. Vaish will be responsible for overseeing and designing the Company's global regulatory strategy and will report to the Company's President and Chief Executive Officer, Daniel J. O'Connor. Ms. Vaish is an experienced leader in U.S. and global regulatory affairs with extensive experience in oncology drug development ranging from pre-clinical to commercial products in many fields, including prostate and breast cancer. She has held senior regulatory leadership positions at Celgene, Merck and Kite Phar

      8/1/23 8:30:00 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Appoints Jared Kelly as General Counsel

      SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ:AMAM), today announced the appointment of Jared Kelly as Senior Vice President, General Counsel and Corporate Secretary. After practicing for more than ten years at large corporate law firms, Mr. Kelly brings his extensive experience advising public companies on corporate governance, financing transactions and mergers and acquisitions to Ambrx. He will be responsible for developing and overseeing the legal strategy of the Company and for providing legal guidance to the Company's board of directors, executive management team and other business units. Mr. Kelly is an experienced public company lawyer who

      6/5/23 8:30:00 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Hermans Kate

      4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)

      3/7/24 7:23:35 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Loesberg Janet

      4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)

      3/7/24 7:19:43 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • O'Connor Daniel J. returned 48,202 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)

      3/7/24 5:46:49 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JMP Securities initiated coverage on Ambrx Biopharma with a new price target

      JMP Securities initiated coverage of Ambrx Biopharma with a rating of Mkt Outperform and set a new price target of $15.00

      9/25/23 7:12:57 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BTIG Research initiated coverage on Ambrx Biopharma with a new price target

      BTIG Research initiated coverage of Ambrx Biopharma with a rating of Buy and set a new price target of $26.00

      9/12/23 7:13:06 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • RBC Capital Mkts initiated coverage on Ambrx Biopharma with a new price target

      RBC Capital Mkts initiated coverage of Ambrx Biopharma with a rating of Outperform and set a new price target of $29.00

      7/31/23 7:17:15 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Financials

    Live finance-specific insights

    See more
    • Ambrx to Commence Trading on Nasdaq

      Company to Transfer Stock Exchange Listing from NYSE to Nasdaq Ticker symbol will remain "AMAM" Ambrx Biopharma Inc. (NYSE: AMAM) ("Ambrx" or "the Company") today announced that it will voluntarily transfer its stock exchange listing to the Nasdaq Stock Market from the New York Stock Exchange, effective March 16, 2023 after market close. Ambrx's American Depositary Shares are expected to begin trading as a Nasdaq-listed security on March 17, 2023. The Company will retain its current ticker symbol "AMAM". "The listing of our stock on the Nasdaq represents a significant milestone in our growth as a publicly-traded company and is an important step that will help facilitate our mission to di

      3/6/23 9:00:00 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Biopharma Inc. Announces Strategic Reprioritization and Provides Corporate Update

      - Company now focused on earlier stage engineered antibody drugs for cancer therapies, including new lead asset ARX517 – - Revised focus and projected cost-reductions expected to extend cash runway into 2025 – - Ambrx to host a conference call today at 5:00 p.m. EST / 2:00 p.m. PST - SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE:AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced a strategic reprioritization of its pipeline and provided a corporate update. The strategic assessment considered the company's cash runway, pipeline near term v

      10/18/22 4:05:00 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Biopharma to Host Corporate Update Conference Call

      SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE:AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the company will host a corporate update conference call and live webcast on October 18, 2022 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time, to discuss the company's strategic review of its development pipeline. Individuals interested in listening to the conference call may do so by registering via the webcast link in the investor relations section of the company's website at: www.ambrx.com. To access the call by phone, please use the reg

      10/11/22 4:05:00 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care